Cargando…

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors

BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beyranvand Nejad, Elham, Labrie, Camilla, van Elsas, Marit J, Kleinovink, Jan Willem, Mittrücker, Hans-Willi, Franken, Kees L M C, Heink, Sylvia, Korn, Thomas, Arens, Ramon, van Hall, Thorbald, van der Burg, Sjoerd H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061866/ https://www.ncbi.nlm.nih.gov/pubmed/33879600 http://dx.doi.org/10.1136/jitc-2021-002460

Ejemplares similares

Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy
por: Beyranvand Nejad, Elham, et al.
Publicado: (2020)

Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models
por: van Elsas, Marit, et al.
Publicado: (2020)

Interleukin‐6‐mediated resistance to immunotherapy is linked to impaired myeloid cell function
por: Beyranvand Nejad, Elham, et al.
Publicado: (2020)

Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy
por: van Elsas, Marit J, et al.
Publicado: (2023)

Future Challenges in Cancer Resistance to Immunotherapy
por: van Elsas, Marit J., et al.
Publicado: (2020)

Delayed vaccine-induced CD8(+) T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication
por: van der Sluis, Tetje C, et al.
Publicado: (2023)

NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division
por: Borst, Linda, et al.
Publicado: (2021)

Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S
por: Harryvan, Tom J, et al.
Publicado: (2022)

CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
por: Duurland, Chantal L, et al.
Publicado: (2022)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Kortekaas, Kim E, et al.
Publicado: (2021)

Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
por: Sandker, Gerwin Gerhard Wemke, et al.
Publicado: (2023)

Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival
por: Abdulrahman, Ziena, et al.
Publicado: (2022)

CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden
por: van den Bulk, Jitske, et al.
Publicado: (2023)

Adenoviral vaccines promote protective tissue-resident memory T cell populations against cancer
por: van der Gracht, Esmé TI, et al.
Publicado: (2020)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection
por: Beyranvand Nejad, Elham, et al.
Publicado: (2019)

Immune involvement of the contralateral hemisphere in a glioblastoma mouse model
por: Crommentuijn, Matheus H W, et al.
Publicado: (2020)

Targeted delivery of miR-99b reprograms tumor-associated macrophage phenotype leading to tumor regression
por: Wang, Liang, et al.
Publicado: (2020)

The Breadth of Synthetic Long Peptide Vaccine-Induced CD8(+) T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection
por: Panagioti, Eleni, et al.
Publicado: (2016)

TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism
por: Canè, Stefania, et al.
Publicado: (2021)

Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression
por: Finisguerra, Veronica, et al.
Publicado: (2023)

Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway
por: van Pul, Kim M, et al.
Publicado: (2020)

Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
por: Boelaars, Kelly, et al.
Publicado: (2023)

Saponin-based adjuvants enhance antigen cross-presentation in human CD11c(+) CD1c(+) CD5(−) CD163(+) conventional type 2 dendritic cells
por: Ho, Nataschja I, et al.
Publicado: (2023)

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
por: van Rees, Dieke J, et al.
Publicado: (2022)

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
por: van Helden, Mary J, et al.
Publicado: (2023)

TEIPP peptides: exploration of unTAPped cancer antigens
por: Marijt, Koen A., et al.
Publicado: (2019)

CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
por: Zammarchi, Francesca, et al.
Publicado: (2020)

Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody
por: van Elsas, Marit J., et al.
Publicado: (2022)

Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch
por: Cornel, Annelisa M, et al.
Publicado: (2022)

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
por: van der Woude, Lieke L, et al.
Publicado: (2022)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions
por: Lameris, Roeland, et al.
Publicado: (2023)

Computer-assisted surgery in orthopedic oncology: Technique, indications, and a descriptive study of 130 cases
por: Gerbers, Jasper G, et al.
Publicado: (2014)

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
por: Yang, Rui, et al.
Publicado: (2020)

Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes
por: Raaijmakers, Tonke K, et al.
Publicado: (2020)

Local anesthetics elicit immune-dependent anticancer effects
por: Bezu, Lucillia, et al.
Publicado: (2022)

Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes
por: Solvay, Marie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m2667dn29vhfebaefg4o59mjjl